Rare coding variants of ATP-binding cassette protein A13 (ABCA13) contribute to the risk of neurological disorders, but little is known about the physiological function of ABCA13 and how single nucleotide polymorphisms (SNPs) affect it. Here, we examined the effects of neurological disorder-related SNPs ABCA13, T4031A and R4843C in the context of ABCA1, and found that the former SNP (T1088A in ABCA1) severely impaired the ABCA1 functions of apolipoprotein A-I (apoA-I) binding and cholesterol efflux. The antibody against mouse ABCA13 reacted with neurons in the cerebral cortex, hippocampus, and cerebellum. These results suggest that the T4031A replacement affects the function of ABCA13 in the brain.
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Key words: ABC protein; ATP-binding cassette protein A13 (ABCA13); neurological disorders; single nucleotide polymorphisms (SNPs); neurons A member of the ABC protein family ATP-binding cassette protein A13 (ABCA13), is predicted to have the typical structure of full-size ABC proteins, consisting of two transmembrane domains (TMDs), each containing six transmembrane -helices and two nucleotide binding domains (NBDs). ABCA13 is the largest member of the ABC protein family and has a long N-terminal, including more than 3,500 amino acids. It is expressed as mRNA in the human trachea, testis, bone marrow, brain, and other tissues, [1] [2] [3] but its physiological function remains unknown.
Eukaryote ABC proteins can be divided into seven subfamilies, A to G, and ABCA13 belongs to ABCA subfamily. It shares highest similarity with ABCA12 (59%), followed by ABCA1 (51%), ABCA4 (51%), and ABCA7 (50%). Their transport substrates have been reported to be lipids, glucosylceramide for ABCA12, 4) cholesterol and phosphatidylcholine (PC) for ABCA1, 5) N-retinylidenephosphatidylehtanolamine for ABCA4, 6) and PC for ABCA7. 7) Considering their sequence homology, ABCA13 is predicted to transport lipid molecules.
Recent genome-wide association studies (GWASs) have indicated that some rare coding variants of ABCA13 contribute significantly to the risk of neurological disorders such as schizophrenia, bipolar disorder, and depression.
3) This suggests that ABCA13 plays an important role in the brain, in that dysfunction of it causes neuronal disorders, but to date little is known about the physiological function of ABCA13 or the effect of ABCA13 SNPs on its function.
In this study, we focused on two SNPs in ABCA13 that reside in NBDs. The homology of amino acid sequence between the TMDs of ABCA13 and ABCA1 is only 44.5%. Hence it is difficult to elucidate the effect of ABCA13 SNPs in TMDs on the function of ABC protein using ABCA1 as template. On the other hand, NBDs have special motifs such as Walker A, Walker B, and the ABC signature motif, which are highly conserved among ABC proteins and confer the ATP hydrolysis function on the proteins. Because the NBDs of ABCA13 are similar (70.7%) to those of ABCA1 and the function of ABCA1 has been investigated in detail, we used ABCA1 as template to study the effects of ABCA13 SNPs on the functions of ABC proteins. Two SNPs of ABCA13, T4031A and R4843C, were inserted into the corresponding amino acid residues of ABCA1, T1088A and K2031C. Then we examined the effects of these alterations on the subcellular localization and function of ABCA1.
Materials and Methods
Plasmids and transfection. Site-directed mutations were introduced into ABCA1 using In-Fusion (Takara Bio, Ohtsu, Japan). The integrity of the mutated DNA was confirmed by sequencing. ABCA1 cDNA was fused with green fluorescent protein (GFP) at the C-terminus and inserted into the pIRESpuro3 vector (Takara Bio). Using Lipofectamine LTX and Plus Reagent (Life Technologies Japan, Tokyo), plasmids were introduced into human embryonic kidney (HEK) 293 cells. Stable transformants were selected in the presence of 1 mg/mL of Puromycin. ABCA1 was detected by mouse monoclonal anti-GFP antibody (sc-9996, Santa Cruz, CA), and vinculin, as internal control, was detected by mouse monoclonal anti-vinculin antibody (V9131, Sigma-Aldrich Japan, Tokyo) in immunoblotting analysis.
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Cellular lipid release assay. HEK293 cells were incubated in the presence of 10 mg/mL of apolipoprotein A-I (apoA-I) for 24 h in Dulbecco's Modified Eagle's Medium (DMEM) containing 0.02% bovine serum albumin (BSA). The cholesterol content in the medium was determined by colorimetric enzyme assay, as described previously.
8)
Biotinylation of cell-surface proteins. Cells were incubated with 0.5 mg/mL of sulfo-N-hydroxysuccinimidobiotin (sulfo-NHS-biotin) for 30 min on ice in the dark. The cell lysate (200 mg) was reacted with immobilized monomeric avidin gel (Thermo Fisher Scientific, Rockford, IL) for 3 h at 4 C and precipitated, as described previously.
9)
Sulfo-NHS-biotin was purchased from Pierce. We found that the amount of wild-type ABCA1 on the plasma membrane was more variable than the non-functional ABCA1MM, probably because the former is regulated by various post-translational modifications.
Hence the relative amount of cell-surface ABCA1 was compared to ABCA1MM.
ApoA-I binding assay. HEK293/ABCA1 cells were incubated with 5 mg/mL of Alexa546-conjugated apoA-I at 37 C for 15 min. Unbound apoA-I was removed, and then the cells were fixed with 4% paraformaldehyde and observed by confocal microscopy (LSM 5 Pascal, Carl Zeiss Japan, Tokyo). 10) To compare apoA-I binding, the intensity of Alexa546 was analyzed with Image J and normalized to GFP intensity.
Immunohistochemical staining. Sagittal sections from adult mouse brains were cut on a cryostat. Material handling and immunostaining were done by methods described previously. 11) In brief, the cryostat sections were fixed in 4% (v/v) formaldehyde for 20 min at 4 C. The sections were incubated in rabbit polyclonal antibody against ABCA13 (1:300) overnight at 4 C. This was followed by incubation with peroxidase-labeled anti-rabbit serum (Histofine Simple Stain MAX-PO(R) (Nichirei Biosciences, Tokyo). The colorimetric reaction was carried out with 0.3 mg/mL of diaminobenzidine and 0.003% H 2 O 2 , and the nuclei were counterstained with hematoxylin. Anti-ABCA13 antibody was generated against 13 amino acids in the C-terminus of mouse ABCA13.
Statistical analysis.
Values are presented as the means AE SD (n ¼ 3). Statistical significance was determined by the Dunnet test. 
Results
ApoA-I-dependent cholesterol efflux from HEK/ ABCA1-SNP mutants ABCA1 exports cholesterol from cells in the presence of apoA-I. To examine the effect of the two diseaserelated SNPs of ABCA13, we introduced several changes in amino acid residues into ABCA1-GFP (Fig. 1) . T4031 in ABCA13 is highly conserved in NBD1 among all ABCA subfamily proteins, and corresponds to T1088 in ABCA1. R4843 in ABCA13, on the other hand, is not conserved among ABCA subfamily proteins, but ABCA1 contains a related amino acid residue, lysine, at position 2,031 (Fig. 1) . Hence we established HEK293 cells that stably expressed ABCA1 containing ABCA13 SNPs, ABCA1-T1088A, ABCA1-K2031C, and ABCA1-K2031R (as control). Then we examined cholesterol efflux in the presence of apoA-I. We also analyzed cholesterol efflux from cells expressing non-functional ABCA1-MM, in which two critical lysine residues in the NBDs were replaced with methionine residues and a Tangier disease mutant, ABCA1-W590S. When the cells were incubated with a physiological concentration of apoA-I (10 mg/mL) for 24 h, a significant amount of cholesterol was transported from them to the medium by ABCA1 (Fig. 2A) , but we found that ABCA1-MM did not mediate apoA-Idependent cholesterol efflux, and that W590S Tangier mutation reduced cholesterol efflux by about 55%, as reported previously. 12) Furthermore, the T1088A SNP drastically reduced cholesterol efflux, by about 90%. However, the K2031C SNP did not significantly affect cholesterol efflux as compared to the wild type or K2031R (Fig. 2A) .
ApoA-I binding of HEK/ABCA1-SNP mutants at the plasma membrane
We have reported that the first step in high-density lipoprotein (HDL) formation is apoA-I binding to the extracellular domains of ABCA1. 13) Hence we examined to determine whether the loss in the cholesterol efflux ability of T1088A was due to a change in apoA-I binding. When HEK/ABCA1 was incubated with 5 mg/ mL of Alexa Fluor 546-conjugated apoA-I at 37 C for 15 min, apoA-I binding to the cell surface was clearly observed. W509S retained the ability to interact with apoA-I, while MM abolished that ability, as found previously. 10) Furthermore, apoA-I binding was severely reduced (by 76%) by the T1088A SNP, while K2031C showed only a mild reduction (44%) (Fig. 2B) . These results suggest that HEK/ABCA1-T1088A has low apoA-I-binding activity.
Total and surface expression of the ABCA1-SNP mutants
The fluorescence intensity of the GFP that fused to the C-terminus of ABCA1 suggests that T1088A did not severely impair total expression as compared to the wildtype ABCA1 (Fig. 2B) , but it was difficult to compare surface expression because ABCA1 also located to the intracellular vesicles. 14) Hence we examined the relative surface expression of ABCA1 by biotinylating cellsurface proteins. The total expression of T1088A was similar to that of the wild-type and the other mutants, with the exception of W590S (Fig. 3A) . However, the amount of biotinylated ABCA1-T1088A was low as compared with the other mutants, and the fraction of surface localization was reduced by about 70% as compared to ABCA1-MM (Fig. 3B) . To confirm this change in the subcellular localization of ABCA1-T1088A, we examined glycosylation via EndoH, which cleaves within the chitobiose core of high mannose-type N-linked oligosaccharides, and PNGaseF, which cleaves all types of N-linked oligosaccharides. For K2031C and wild-type K2031R, most of the protein was resistant to EndoH, but 50% or more of ABCA1-T1088 was sensitive to EndoH (Fig. 4) , suggesting that the T1088A mutation caused improper folding of the protein. Hence it did not pass ER quality control.
Detection of ABCA13 in the mouse brain
The above results suggest that SNP T4031A, reported to be linked with risk of neurological disorder, can Cell lysate (20 mg) was treated with glycosidases, Endo H (lanes H), or PNGaseF (lanes F). As control H 2 O was added to the lysate (lanes C). The cell lysate was then subjected to 7% SDS-PAGE, followed by immunoblot with anti-GFP antibody. Vinculin was detected as internal control. A, HEK293/ABCA1-GFP cells were biotinylated and precipitated as described in ''Materials and Methods,'' and were detected with anti-GFP antibody. An aliquot (1/10) of the cell lysate, subjected to biotinylation, was also analyzed. Vinculin was examined as internal control. B, Quantification of the relative amounts of cell-surface ABCA1. The intensities of the bands from immunoblotting were quantified with Multi Gauge (Fujifilm, Tokyo). Experiments were done in triplicate.
impair the function of ABCA13, but little is known about its localization in the brain. To determine the localization of ABCA13, we generated polyclonal antibodies against 13 amino acids in the C-terminus of mouse ABCA13 and performed immunohistochemistry on mouse-brain sections. We found that large cells in the cerebral cortex, dentate granule cells, and Purkinje cells in the cerebellum were stained with the ABCA13 antibody (Fig. 5 ).
Discussion
In this study, we examined the effects of neurological disorder-related SNPs of ABCA13, T4031A, and R4843C, in the context of ABCA1, and found that the former SNP severely impaired ABCA1 function. Because the antibody against ABCA13 reacted with neuronal cells in the cerebral cortex, hippocampus, and cerebellum, T4031A replacement in ABCA13 could affect its function in neurons.
T1088 resides downstream of the conserved Walker B motif of NBD1, and K2031 is located between the Walker A and B motifs. No SNPs have been reported at these positions in ABCA1, although more than 100 coding variants have been identified in ABCA1.
15) Using PolyPhen-2, T1088A and K2031C were both predicted to impair the function of ABCA1, with scores of 1.000 and 0.999, respectively, 16, 17) but the effects of T1088A and K2031C replacement were quite different. T1088A severely impaired the subcellular localization and the functions of ABCA1, specifically apoA-I binding and cholesterol efflux, but K2031C showed only a mild effect on apoA-I binding, and no effect on cholesterol efflux. Based on the structure of mouse mdr1a, 18) T1088A can be mapped at the interface between two NBDs and K2031 at the domain protruding to the outside (Fig. 6) . The T1088A replacement of a hydrophilic by a hydrophobic amino acid might change the environment around its side chain and affect protein folding. Biotinylation of surface proteins and glycosylation analysis suggested that some fraction of ABCA1-T1088A reached the plasma membrane. Hence it is likely that this replacement also impairs ATP hydrolysis, and that this caused a dramatic decrease in cholesterol efflux by ABCA1. On the other hand, K2031C did not affect the subcellular localization or cholesterol efflux of ABCA1. The R4843C replacement in the protruded domain of NBD2 in ABCA13 might have an effect The putative locations of the ABCA13 SNPs in NBDs are shown in a mouse mdr1a structural model. 18) Some common motifs of ABC proteins are shown in different colors: Walker A (red), Walker B (blue), and H-loop (orange). The putative locations of Thr4031 and Arg4843 are shown in pink (Ala582 in mdr1a) and yellow (His1151) respectively. In the lower panel, structural models of NBD1 and NBD2 are viewed from the interface between the two NBDs, and the locations of the SNP are indicated by circles. Thr4031 is located at the interface between the two NBDs and Arg4843 in the domain protruding to the outside. specific to ABCA13, such as protein-protein interaction in neuronal cells.
A previous study reported that ABCA13 is expressed in dentate gyrus granule cells and ventricular areas, including choroid plexus and ependymal cells. 3) In the present study, we found for the first time that ABCA13 is expressed in Purkinje cells, the only projection neurons in the cerebellum (Fig. 5 ).
There have been many studies of the association between ABC proteins and Alzheimer's disease, 19) but, very little is known regarding the link between ABC proteins and other neurological disorders, such as schizophrenia and bipolar disorder. Although the physiological function of ABCA13 remains unresolved, this study suggests an important function of ABC protein in proper brain function. Our findings also highlight a new methodology for ascertaining the mechanisms of neurological disorders.
